Burden and the latest treatment progress of mild asthma

Bronchial asthma (asthma) is an important disease affecting human health worldwide.The prevalence of mild asthma accounts for more than half of all asthma patients, and the burden of disease is severe.Because the symptoms of mild asthma are not obvious, current treatments focus more on symptom relief in the acute phase, which leads to a relatively poor understanding of the benefits of long-term anti-inflammatory treatment, and the patient′s compliance is relatively poor.Therefore, the risk of acute exacerbation, progresses to moderate-severe asthma, even chronic obstructive pulmonary disease may increase.Recent studies have shown that as-needed inhalation corticosteroids and long-acting β2 agonists can relieve symptoms, fight inflammation, improve quality of life, improve lung function, and effectively prevent acute asthma attacks, improve patient compliance.This article reviews the epidemiology, disease burden, current Chinese treatment status, and the latest treatment progress of mild asthma, by referring the international guidelines and consensus. Key words: Asthma; Cost of illness; Fast-acting β2 agonists; Treatment